Evidence map›Paper›PMID 40923110›Full record

SynthesisBrain and behavior2025

Suicide Ideation, Attempts, and Mortality in Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Omid Mirmosayyeb, Homa Khodadadi, Aynaz Mohammadi, Motahareh Abbasi, Saeed Vaheb, Mohammad Yazdan Panah, Mohammad Mohammadi, Vahid Shaygannejad

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Suicide in neurodegenerative diseases: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omid MirmosayyebIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-3756-2985
Homa KhodadadiIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Aynaz MohammadiSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-3291-1293
Motahareh AbbasiIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Saeed VahebIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad Yazdan PanahIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad MohammadiSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-9375-5549
Vahid ShaygannejadIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiving with multiple sclerosis (MS) means facing significant obstacles in managing the unpredictable nature of this lifelong condition. Studies highlight a concerning connection between the disease and an elevated risk of suicide. In this study, we assessed the prevalence of suicide and suicide mortality risk in people with MS (PwMS).

methodsA comprehensive and systematic search of Medline, EMBASE, Scopus, and Web of Science databases was conducted. Studies of any design were included if they reported at least one of the following outcomes: (1) the prevalence of suicide ideation, suicide attempts, suicide deaths, and the proportion of suicide deaths among total deaths in MS populations (2) the risk of suicide mortality in PwMS compared to healthy controls.

resultsThe systematic review and meta-analysis included 64 studies across 19 countries, predominantly from Europe and North America, encompassing over 200,000 PwMS. The pooled prevalence of suicide ideation was 22.6% (95% CI: 16.9-28.3). Suicide attempts were reported at 3.4% (95% CI: 1.6-5.2), while suicide mortality was 0.5% (95% CI: 0.3-0.7), accounting for 2.1% (95% CI: 1.5-2.7) of total mortality in PwMS. PwMS had a significantly higher suicide mortality risk compared to healthy controls (standardized mortality ratio [SMR] = 1.49, 95% CI: 1.08-2.05).

conclusionThis study highlights the elevated suicide mortality risk among PwMS, underscoring the urgent need for integrated mental health care in MS management. Future research should explore the impact of disease-modifying therapies, protective factors, and standardized risk assessment tools to improve early intervention and reduce suicidal behavior in this vulnerable population.

Indexed as

Multiple SclerosisSuicidal IdeationSuicideSuicide, AttemptedHumansPrevalencemeta‐analysismortalitymultiple sclerosisprevalencesuicide

Identifiers

PMID40923110
PMCPMC12417961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.